Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 36Neoplasm Metastasis 12Neoplasms 10Colorectal Neoplasms 5Thyroid Neoplasms 4Thyroid Cancer, Papillary 4Multiple Myeloma 4Leukemia, Hairy Cell 4Hematologic Neoplasms 4Skin Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Thyroid Carcinoma, Anaplastic 2Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms by Site 2Neoplasms by Histologic Type 2Lymphoma, Non-Hodgkin 2Brain Neoplasms 2Thyroid cancer, follicular 1Thrombocytosis 1Sarcoma, Clear Cell 1Sarcoma 1Relapsed Pediatric Solid Tumor 1Rare Tumour 1Rare Tumor 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Everolimus 5Cetuximab 2volagidemab 1tanezumab 1pembrolizumab 1inavolisib 1Vemurafenib 1Trimetazidine 1Sirolimus 1Secretin 1SF 1126 1Pharmaceutical Preparations 1Panobinostat 1Oxaliplatin 1Nivolumab 1NVP-BKM120 1Leucovorin 1Irinotecan 1Fulvestrant 1Fluorouracil 1Drug Therapy 1Capecitabine 1CB-839 1CA-19-9 Antigen 1Bevacizumab 1Aspirin 1Alpelisib 111-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hereditary Sensory and Autonomic Neuropathies × Vemurafenib × Clear all
NCT01942993 2020-09-30

The Effects of Treatment With Vemurafenib on the Immune System in Advanced Melanoma

Icahn School of Medicine at Mount Sinai

Phase 2 Terminated
3 enrolled 2 charts
Dermatologic

Melanoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡